Author name: Leonardo Arias

Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in eye-popping numbers. BioSpace rounds up the biggest raises so far this year.

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products on their own.

The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, where he had been the head of the Center for Biologics Evaluation and Research for less than three months.

Venture capital investment across the healthcare sector slowed in the first half of the year, but investors are spending on health tech — especially artificial intelligence, according to a report by Silicon Valley Bank.

The company previously forecast an up to 300 million euro tariff impact in 2025 before the U.S. struck agreements with China and the European Union.

Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and domestic policy bill, including cuts to Medicaid, will be minimal.

The beleaguered company plans to focus on business fundamentals, cut Medicare Advantage plans, raise prices and forge a new relationship with regulators as it slogs its way back to favored status with Wall Street.

Venture capital investment across the healthcare sector slowed in the first half of the year, but investors are spending on health tech — especially artificial intelligence, according to a report by Silicon Valley Bank.

CEO Rob Davis referred to the cost reduction program as a ‘reallocation’ rather than a cut, with the savings to be reinvested to support up to 20 new product launches.

Pascal Soriot’s comments came during AstraZeneca’s Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, with its cancer portfolio driving earnings despite clinical roadblocks.